Dolasetron
Indication :
- Prevention of cancer chemotherapy induced vomiting and post-operative vomiting
Dosing :
<2 years:
Safety not established
2-16 years:
1.8 mg/kg orally 1 hour before chemotherapy. 0.35 mg/kg IV 15 mins before cessation of anesthesia for prevention of post-operative vomiting.
Max dose:
100 mg/dose orally, 12.5 mg/dose IV.
Adverse Effect :
Headache, diarrhea, dizziness, brady-tachycardia, hypo-hypertension, fever, urinary retention, itching.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function |
| <10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unlikely to be dialysed. Dose as in normal renal function |
| HD | Unlikely to be dialysed. Dose as in normal renal function |
| HDF/High flux | Unlikely to be dialysed. Dose as in normal renal function |
| CAV/VVHD | Unlikely to be dialysed. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are recommended.